Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines...

Full description

Bibliographic Details
Main Authors: Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E. Magnusson
Format: Article
Language:English
Published: MDPI AG 2017-02-01
Series:International Journal of Molecular Sciences
Subjects:
metastatic renal cell carcinoma
sunitinib
sorafenib
hypertension
tyrosine kinase inhibitors
vascular endothelial growth factor
Online Access:http://www.mdpi.com/1422-0067/18/2/461

Internet

http://www.mdpi.com/1422-0067/18/2/461

Similar Items